CardioFocus is Becoming a Force to Be Reckoned with in AFib Market

CardioFocus is quickly positioning itself to be a dominant player in the growing atrial fibrillation (AFib) treatment market. Regulatory approvals coupled with triple-digit-growth are helping to shape the Marlborough, MA-based into a force to be reckoned with in a market filled with intense competition. Last week, CardioFocus further strengthened its presence in the market by receiving CE mark for the HeartLight X3 System. The device is the latest generation of the company’s AFib treatment technology and could help the firm continue to thrive Europe, a market set to reach between 14 million and 17 million by 2030. CardioFocus’ President and Chief Commercial Officer Omari Bouknight spoke with MD+DI last week about the HeartLight X3’s CE mark and plans to eventually bring the new generation of the technology to the U.S. market. The HeartLight X3 System is a third-generation technology building upon the advanced features of the HeartLight Endoscopic Ablation System, which performs pulmonary vein isolation (PVI) using laser energy to create lines of scar tissue to block the abnormal electrical pathways that cause AFib. Join us for New England’s Premier Medtech Event Held at the Boston Convention Exhibition Center in Boston, MA, May 15-16.  “What makes the [HeartLight] X3 system unique is that it allows the user to create a continuous lesion around the pulmonary vein,â€...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Source Type: news